Geron (GERN) FCF Margin (2010 - 2026)

Geron (GERN) posted FCF Margin of 121.35% for Q1 2026, down 826.0% sequentially from 16.72% in Q4 2025, and down 20.0% YoY from 151.69% in Q1 2025.

Geron (GERN) FCF Margin (2010 - 2026) Analysis & Trends

Geron has reported FCF Margin for 17 years, with the latest figure at 121.35% in Q1 2026.

Quarterly FCF Margin fell 20.0% year-over-year to 121.35% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 783.21% (down 27011.0% YoY) and the FY2025 annual result came in at 2884.83%, up 4106267.0% from the prior year.
FCF Margin slipped to 121.35% in Q1 2026 per GERN's latest filing, from 16.72% in the prior quarter.
Over five years, FCF Margin peaked at 19159.81% in Q4 2023 and troughed at 211666.67% in Q1 2023.
A 5-year average of 28136.83% and a median of 6063.49% in 2024 frame the typical range for FCF Margin.
The sharpest annual moves came in 2023 and 2024: FCF Margin plunged 18400488 bps in 2023, then soared 19091930 bps in 2024.
Over 5 years, FCF Margin stood at 34292.23% in 2022, then soared by 156 bps to 19159.81% in 2023, then sank by 99 bps to 151.27% in 2024, then sank by 89 bps to 16.72% in 2025, then plunged by 826 bps to 121.35% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 121.35%, 16.72%, and 28.75% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.94 Bn	132.09 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	86.59 Bn	78.60 Bn	3.93 Bn	13.35%
3	Argenx Se	65.67 Bn	60.49 Bn	1.37 Bn	-
4	Moderna	57.81 Bn	52.67 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	42.25 Bn	37.15 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.76 Bn	28.45 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.41 Bn	10.02 Bn	668.28 Mn	41.07%
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.24 Bn	26.41 Bn	-	70.82%
10	Geron	1.05 Mn	-299.80 Mn	-	-27.53%

Download Data